Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1001 plus FP vs placebo plus FP in unresectable esophageal squamous cell carcinoma
CTR20192467Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sugemalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by CStone Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
sugemalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20192467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192467.